树突状细胞融合瘤苗在肿瘤免疫中的研究进展

Study progress about dendritic/tumor fusion cell-based vaccine in tumor immunotherapy

树突状细胞（DC）是诱导初始免疫应答反应的专职抗原提呈细胞，它能捕获抗原并加工处理成小分子多肽，通过MHCⅠ类和Ⅱ类分子提呈给T细胞和B细胞。DC与肿瘤细胞融合所获得的融合瘤细胞，在共刺激信号存在的条件下，能够加工处理细胞内许多已知和未知的肿瘤相关抗原（TAA），并通过MHCⅠ类和Ⅱ类分子提呈。目前，DC融合瘤苗在动物和临床研究中取得了许多进展，已成为肿瘤免疫治疗的热点之一。

Dendritic cells （DCs） are potent professional antigen-presenting cells which are able to in- duce primary immune responses. DC can capture and process antigens into small-molecule peptides and present them to T cells and B cells through MHC class Ⅰ and Ⅱ molecules. An alternative approach to the induction of antitumor immunity is the use of fusion of DC and tumor cells. In this approach, a broad spectrum of known and unknown tumor-associated antigens （TAA） are presented by MHC class Ⅰ and Ⅱ molecules. In animal and clinical studies, dendritic/tumor fusion ceil-based vaccine has made much progress and become a focus of the tumor immunotherapy.